Business Wire Gamida Cell Appoints Julian Adams, Ph.D., Chairman and Chief Executive Officer
Pharmaceutical Filtration Market Analysis and Forecast to 2023 - Research and Markets
LivaNova stipula una Lettera di Intenti vincolante per la vendita della sua Business Franchise Cardiac Rhythm Management a MicroPort Scientific Corporation per circa 190 Milioni di dollari
LivaNova Enters into Binding Letter of Intent to Sell its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation for $190 Million
Chugai's Bispecific Antibody Emicizumab Meets Primary Endpoint in Phase lll Study